North America Coagulation Analyzers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Clinical Laboratory Analyzers and Point-of-Care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Ti

North America Coagulation Analyzers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Clinical Laboratory Analyzers and Point-of-Care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others)

The North America coagulation analyzers market is expected to grow from US$ 1,802.76 million in 2022 to US$ 2,529.13 million by 2028. It is estimated to grow at a CAGR of 5.8% from 2022 to 2028.

Increasing Prevalence of Blood Disorders Drives North America Coagulation Analyzers Market Growth

A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to measure blood platelet levels and thrombolin and thromboplastin levels accurately. According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. In the US, approximately 1 in 5,000 newborn males suffer from hemophilia A. According to the National Library of Medicine (NLM), in 2020, approximately 30,000-33,000 males were affected with hemophilia in the US. According to the US Department of Health & Human Services, in 2020, ~100,000 Americans had sickle cell disease (SCD), the most commonly inherited blood disorder. Furthermore, by 2050, the number of people suffering from SCD is expected to grow by ~30%. As per the National Library of Medicine, in 2022, ~1% of all individuals (unselected population) are suffering from von Willebrand disease, i.e., 125 per 1 million. According to National Organization for Rare Disorders, in 2022, in the US, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects approximately 66 adults per 1 million each year. Moreover, in the US, the incidence of ITP in adults is ~3.3 per 100,000/year, while the prevalence is 9.5 per 100,000. Thus, the increasing prevalence of blood disorders is driving the North America coagulation analyzers market t growth.

North America Coagulation Analyzers Market Overview

In North America, the US is the largest market for coagulation analyzers. The growth of this market is primarily driven by rising developments by the market players, and increasing presence of major market players in the US. Further, the growing prevalence of atrial fibrillation is likely to increase the demand for anticoagulant reversal drugs. As per the Centers for Disease Control and Prevention (CDC), in 2019, in the US, AFib was mentioned on ~183,321 death certificates and was the primary cause of death in approximately 26,535 of those deaths. Additionally, the CDC also anticipated that by 2030, 12.1 million people in the US are likely to suffer from AFib. As per the Canadian Task Force on Preventive Health Care, in Canada, the incidence of atrial fibrillation is up to 4.5% per year, with a lifetime risk of ~25% among people older than 40 years.

In addition, the growing incidence of blood disorders is likely to increase the demand for coagulation analyzers in the coming years. For instance, as per the CDC, Hemophilia A affects 1 in 5,000 male births. Approximately 400 babies are born with hemophilia A each year. From 2012 to 2018, ~33,000 males in the US were living with hemophilia. Further, ~300,000 Canadians carry an inherited bleeding disorder gene. One in ten of these people—at least 30,000 Canadians—have symptoms severe enough to require medical care. Many of them have not been properly diagnosed. Only 10,000 people with inherited bleeding disorders are registered in the Canadian network of inherited bleeding disorder comprehensive care clinics. Also, increasing awareness program for blood disorders is likely to favor the market growth in the coming years. Hemophilia Health Education and Prevention Funded Projects is the largest program in CDC’s Division of Blood Disorders. CDC has funded projects that are designed to promote health and prevent complications related to bleeding disorders. Thus, the increasing number of blood disorders, growing incidence of cardiovascular diseases, and rising government support for the prevention of blood disorders in the region are a few factors anticipated to boost the North America coagulation analyzers market growth during the forecast period.

North America Coagulation Analyzers Market Revenue and Forecast to 2028 (US$ Million)

North America Coagulation Analyzers Market Segmentation

The North America coagulation analyzers market is segmented on the basis of product, test, technology, end users, and country.

Based on product, the North America coagulation analyzers market is bifurcated into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzers segment held a larger North America coagulation analyzers market share in 2022.

Based on test, the North America coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, D-dimer testing, platelet function tests, anti-factor XA tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held the largest North America coagulation analyzers market share in 2022.

Based on technology, the North America coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies . The optical technology segment held the largest North America coagulation analyzers market share in 2022.

Based on end users, the North America coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others . The clinical laboratories segment held the largest North America coagulation analyzers market share in 2022.

Based on country, the North America coagulation analyzers market is segmented into the US, Canada, and Mexico. The US dominated the North America coagulation analyzers market share in 2022.

Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc are the leading companies operating in the North America coagulation analyzers market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America coagulation analyzers market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America coagulation analyzers market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution